Importantly, our results revealed that targeting the lactate-NUDT21-FDX1-cuproptosis axis with a combination of the copper ionophore elesclomol and the FDA-approved LDHA inhibitor stiripentol exerted a synergistic antitumor effect in ESCC. Here, FDX1 is linked to esophageal squamous cell carcinoma.